ATHENS, Ga.--(BUSINESS WIRE)--ArunA Biomedical today announced that Steven Stice, Ph.D., co-founder, chief executive and chief scientific officer, will present a corporate update and participate on a panel at the 2018 BIO International Convention occurring June 4-7, 2018 in Boston, MA. On the panel, Dr. Stice will discuss the use of exosomes as a therapeutic for the treatment of central nervous system and neurodegenerative disorders. During the corporate presentation, Dr. Stice will address recent studies that showed the companies neural stem cell-derived extracellular vesicles improved functional recovery in two divergent animal models following ischemic stroke.
Details of the company presentation are as follows:
Title: Neural Exosomes: The Next Generation of CNS Therapeutics
Date: Monday, June 4, 2018
Time: 4:45-5:00pm ET
Location: Theater 4
Details of the panel presentation are as follows:
Title: Harnessing the Body's Regenerative Capabilities – Therapeutic Development from the Clinic to Commercialization
Date: Tuesday, June 5, 2018
Time: 11:00-12:00pm ET
Location: Room 210B, Level 2, Boston Convention and Exhibition Center
To schedule a meeting with ArunA’s management team at the Convention, send them a meeting request through the BIO One-on-One Partnering™ system or contact the team at email@example.com.
Exosomes as Therapeutics
Since their discovery more than 30 years ago, extracellular vesicles — nanometer-sized cell-signaling particles — have been increasingly found to play a role in intercellular communication, capable of delivering functional proteins, mRNA transcripts and miRNA to cells throughout the body. Exosomes have the potential to target any cell in the body and as proved in ArunA’s studies are capable of multiple administrations via IV and of crossing the blood brain barrier non-invasively to reach the site of injury. Exosomes have shown great promise as potential therapeutics and as vehicles to carry drug payloads to the site of injury or disease.
About ArunA Biomedical
At ArunA Biomedical, we are the experts in the design and scaling of neural-derived exosomes, developing a new class of cell-free biologics and cell-mediated drug delivery systems to treat CNS and neurodegenerative disorders. www.arunabio.com